Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer☆

[1]  J. Goldstein,et al.  A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins , 2015, Cell.

[2]  R. Johnstone,et al.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders , 2015, Nature Reviews Drug Discovery.

[3]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[4]  R. Weinberg,et al.  Tackling the cancer stem cells — what challenges do they pose? , 2014, Nature Reviews Drug Discovery.

[5]  Jianxin Shi,et al.  HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc , 2014, Tumor Biology.

[6]  Pei-Ming Yang,et al.  Zebularine inhibits tumorigenesis and stemness of colorectal cancer via p53-dependent endoplasmic reticulum stress , 2013, Scientific Reports.

[7]  Ching-Chow Chen,et al.  Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment. , 2013, Journal of medicinal chemistry.

[8]  O. Sansom,et al.  Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. , 2012, The Journal of clinical investigation.

[9]  M. Durante,et al.  Overcoming resistance of cancer stem cells. , 2012, The Lancet. Oncology.

[10]  S. Kaul,et al.  Evidence-based use of statins for primary prevention of cardiovascular disease. , 2012, The American journal of medicine.

[11]  Oliver Nussbaumer,et al.  Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents , 2012, Clinical Cancer Research.

[12]  C. Tournigand,et al.  Therapeutic strategy in unresectable metastatic colorectal cancer , 2012, Therapeutic advances in medical oncology.

[13]  S. Chadda,et al.  A systematic review of treatment guidelines for metastatic colorectal cancer , 2012, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[14]  A. Levine,et al.  Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway , 2012, Cell.

[15]  M. Sliwkowski,et al.  A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. , 2011, Cancer cell.

[16]  A. Stevens,et al.  Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells. , 2011, The Journal of endocrinology.

[17]  Marco Erreni,et al.  Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer , 2011, Cancer Microenvironment.

[18]  D. Hommes,et al.  Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell ‘stemness’ via the bone morphogenetic protein pathway , 2011, Gut.

[19]  S. Itzkowitz,et al.  Intestinal inflammation and cancer. , 2011, Gastroenterology.

[20]  Alyssa D Gregory,et al.  Tumor-associated neutrophils: new targets for cancer therapy. , 2011, Cancer research.

[21]  Ming-Shiang Wu,et al.  HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells , 2011, PloS one.

[22]  S. Gambhir,et al.  MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. , 2011, Cancer research.

[23]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[24]  Steven M. Lipkin,et al.  The Class I Hdac Inhibitor Mgcd0103 Induces Cell Cycle Arrest and Apoptosis in Colon Cancer Initiating Cells by Upregulating Dickkopf-1 and Non-Canonical Wnt Signaling , 2010, Oncotarget.

[25]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[26]  R. Sundaresan,et al.  Surgical management of colorectal lung metastasis. , 2009, Clinics in colon and rectal surgery.

[27]  D. Steindler,et al.  Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. , 2009, Cancer research.

[28]  N. Mukaida,et al.  Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. , 2009, Cancer research.

[29]  M. Wicha.  Targeting breast cancer stem cells. , 2009, Breast.

[30]  A. Mantovani.  The yin-yang of tumor-associated neutrophils. , 2009, Cancer cell.

[31]  T. Cotter,et al.  Apoptosis and cancer: the genesis of a research field , 2009, Nature Reviews Cancer.

[32]  M. Wicha,et al.  Colon cancer stem cells: implications for prevention and therapy. , 2008, Trends in molecular medicine.

[33]  L. Cantley,et al.  PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.

[34]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[35]  J. Rich,et al.  Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[37]  Jung-Hsin Lin,et al.  Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. , 2008, Cancer research.

[38]  Carl Nathan,et al.  Neutrophils and immunity: challenges and opportunities , 2006, Nature Reviews Immunology.

[39]  H. Welch,et al.  Statins and the Risk of Colorectal Cancer , 2005, The New England journal of medicine.

[40]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[41]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[42]  A. Kettunen,et al.  Intestinal immune responses in wild-type and Apcmin/+ mouse, a model for colon cancer. , 2003, Cancer research.

[43]  T. Noda,et al.  Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. , 1997, Science.

[44]  W C Willett,et al.  Aspirin and the risk of colorectal cancer in women. , 1995, The New England journal of medicine.

[45]  H. Pitot,et al.  A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. , 1990, Science.

[46]  J. Cauley,et al.  Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk. , 2012, Annals of epidemiology.

[47]  D. Jäger,et al.  [Systemic therapy for colorectal cancer]. , 2005, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.